Abstract: Antibodies and antibody conjugates which have been modified by conjugation to, or exposure thereon, of glycoside residues that bind to the human hepatic asialoglycoprotein receptor clear rapidly from the circulation. Use of such modified antibodies and antibody conjugates for imaging and therapy of tumors and infectious lesions is advantageous when the antibodies are administered by a regional route, or when intravenous administration is accompanied by injection of a competitive hepatic lectin binding inhibitor to control the rate of clearance and optimize uptake by the target tissues.